Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of ...

On Friday, Merck & Co Inc (NYSE:MRK) agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.

The drug company will pay an upfront $700 million in cash to privately held Curon Biopharmaceuticals for CN201, a clinical-stage bispecific antibody for B-cell diseases. Curon will also be ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK), a global healthcare leader, has completed the acquisition of a novel bispecific antibody, CN201, from Curon ...

The big pharma is paying $700 million upfront for full global rights to CN201, a CD3xCD19 bispecific which is in early-stage clinical development for B-cell-associated diseases, including cancers ...

The international biopharmaceutical company Merck Group (MSD outside the USA and Canada) has entered into a final agreement with the Chinese private biotechnology company Curon Biopharmaceutical to ...

RAHWAY, N.J., October 01, 2024--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical ...

Merck completes acquisition of investigational B-cell depletion therapy, CN201 from Curon Biopharma: Rahway, New Jersey Thursday, October 3, 2024, 10:00 Hrs [IST] Merck, known as ...

RAHWAY, N.J. - Merck & Co., Inc. (NYSE: MRK), a global healthcare leader, has completed the acquisition of a novel bispecific antibody, CN201, from Curon Biopharmaceutical, enhancing its pipeline with ...

Addition of CN201, a next generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases, broadens and fortifies Merck’s pipeline ...